Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

NCT07643103 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Ph- Acute Lymphoblastic Leukemia (Ph-ALL)

Interventions

DRUG: Inotuzumab Ozogamicin (IO)
DRUG: Venetoclax
DRUG: Blinatumomab
BIOLOGICAL: CD19-directed chimeric antigen receptor (CAR-T) T cells
DRUG: Vincristine
DRUG: Cyclophosphamide
DRUG: Dexamethasone
DRUG: Methotrexate
DRUG: Cytarabine (Ara-C)
DRUG: Prednisone
DRUG: Mercaptopurine 50 mg

Sponsor

Institute of Hematology & Blood Diseases Hospital, China